The largest drug company in Africa, Aspen Pharmacare, has secured a deal with Johnson and Johnson to make and sell a COVID-19 vaccine.
Article continues below
Aspen Pharmacare Holdings Limited confirms that one of its wholly owned South African subsidiaries, Aspen SA Operations, has confirmed a non binding term sheet with Janssen Pharmaceuticalsand Janssen Pharmaceutica, two of the Janssen Pharmaceutical Companies of Johnson and Johnson, that will form the basis for negotiation of a definitive agreement on the manufacture and sale of an Aspen-branded COVID-19 vaccine throughout Africa.
That agreement would expand the existing technical transfer and manufacturing agreements between the parties to grant Aspen SA the rights to:
• manufacture finished SARS-CoV-2 COVID-19 vaccine product from COVID-19 drug substance supplied by Johnson and Johnson; and
• sell the finished form vaccine, to be launched and branded as Aspenovax, to public sector markets in Africa through transactions with designated multilateral organisations and with national governments of member states of the African Union.
In addition, Johnson and Johnson would grant Aspen a license to the enabling intellectual property for this purpose.
The term of the grant of rights and supply of COVID-19 drug substance, subject to the signing of the definitive agreement, would be until 31 December 2026. The non-binding term sheet contemplates a good faith undertaking between the parties to discuss the expansion of the agreement to include any new versions of the drug substance, such as those developed for new variants or as a different formulation for administration as a booster, and the applicable terms thereof.
President Cyril Ramaphosa, African Union COVID champion said: "The effectiveness of our response as the African continent to the COVID-19 pandemic has been severely hampered by the grossly unequal distribution of COVID vaccines across the world.
"Landmark announcement between Africa’s Aspen Pharmacare and Johnson and Johnson is the culmination of months of hard work with, among others, the African Union, Africa Centres for Disease Control and Prevention and the African Vaccine Acquisition Trust, in developing production capacity on the continent.
"This announcement has the potential to make an important contribution to addressing vaccine inequality and building Africa’s capacity to meet its own vaccine needs now and into the future."
Strive Masiyiwa, African Union special envoy on COVID and Head of the AVAT Trust, said: "The biggest and boldest step that Africa took through the Africa Vaccine Acquisition Trust and African Union, was signing a contract with Johnson and Johnson for 400 million doses for the continent, the majority to be produced by Aspen.
"Today’s announcement is an important milestone. It gets us one step closer to securing Africa’s future vaccine production and ensures that the gross vaccine inequality we witnessed in the early part of the pandemic is not repeated."
"We welcome this agreement. It is a major development which will help reduce the inequities Africa is facing in accessing COVID-19 vaccines. This cooperation and technology transfer arrangement is an important step forward towards increasing Africa’s manufacturing capacity and the push to ramp up access to vaccines and other key medical interventions," said Dr Matshidiso Moeti, World Health Organization Regional Director for Africa. ■
A very active and complex mid-May weather pattern is set to produce numerous areas of severe weather, heavy rain, high winds, and anomalous temperatures through this weekend.